MIRM Forecast


Bullish Case: Positive interim results from Volixibat trials and increased adoption of approved indications like LIVMARLI. [uk.investing.com][stocktitan.net]


Bearish Case: High implied volatility and potential for insider selling signal concerns about growth. [simplywall.st][marketbeat.com]


Potential Outcomes: Label expansion success: 30%. Pipeline clinical failure: 40%. Steady-state revenue growth: 20%. Market volatility spike: 10%. [Helium][Helium]


Trading Oracle: Trade debit spreads (long volatility). Bullish case due to mean reversion and positive trial outcomes. 3-6 months outlook. Buy Aug 2024 $40 Call, Sell Aug 2024 $45 Call. Capture upside from expected positive developments with limited risk.


July 20, 2024


Mirum Pharmaceuticals Forecast

MIRM      Mirum Pharmaceuticals











Correlated Assets

Assets that tend to move strongly with MIRM



VFC Forecast + Options Trading Strategies   VFC  VF (0.27)


LI Forecast + Options Trading Strategies   LI  Li Auto (0.13)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (-0.34)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.37)



Uncorrelated Assets

Assets with little price relationship to MIRM



LI Forecast + Options Trading Strategies   LI  Li Auto (0.13)


VFC Forecast + Options Trading Strategies   VFC  VF (0.27)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (-0.34)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.37)



Anticorrelated Assets

Assets that tend to move strongly against MIRM



VFC Forecast + Options Trading Strategies   VFC  VF (0.27)


LI Forecast + Options Trading Strategies   LI  Li Auto (0.13)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (-0.34)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.37)





Become a more profitable investor with AI optimized trading strategies






×

Chat with MIRM


 Ask any question about MIRM!